Business Overview: Akebia Therapeutics, Inc. (NASDAQ: AKBA)

---

Executive Summary

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease. Its two commercial products are Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis, and Auryxia (ferric citrate), an approved oral iron-replacement therapy used both to control serum phosphorus in dialysis patients and to treat iron-deficiency anemia in adults with CKD not on dialysis.

Headquartered in Cambridge, Massachusetts, Akebia is one of a small number of companies with an approved oral alternative to injectable erythropoiesis-stimulating agents (ESAs) for anemia management in the large and growing dialysis and CKD patient population.

---

1. Core Business Model & How They Work

Akebia's model centers on commercializing FDA-approved, chronic-use kidney-disease therapies sold primarily to dialysis providers, nephrologists, and pharmacy channels, supported by ongoing clinical and regulatory work to expand product labels and indications.

[ Kidney-Disease-Focused R&D ] ➡️ [ FDA Approval (Vafseo, Auryxia) ] ➡️ [ Sales to Dialysis Organizations & Nephrology Practices ] ➡️ [ Chronic, Recurring Prescription Revenue ] ➡️ [ Lifecycle Management / Label Expansion ]

Key Operational Drivers

1. Oral Alternative to Injectable Anemia Therapy: Vafseo offers dialysis patients and providers an oral option for anemia management, differentiated from injectable ESAs (like Amgen's Epogen/Aranesp) that require in-clinic administration.
2. Dialysis Organization Relationships: Because most U.S. dialysis care is delivered through a small number of large dialysis organizations (DaVita and Fresenius Kidney Care dominate the market), commercial success depends heavily on securing favorable formulary and reimbursement arrangements with these large customers.
3. Chronic Disease, Recurring Revenue: CKD and dialysis-related anemia are chronic conditions requiring ongoing treatment, supporting a recurring prescription revenue model once a patient is started on therapy.
4. Regulatory & Reimbursement Navigation: Commercial success is closely tied to Medicare's dialysis bundled-payment system (the ESRD Prospective Payment System), which determines how new therapies like Vafseo are reimbursed within the bundle.

---

2. Business Segments

Akebia operates as a single integrated biopharmaceutical business focused on kidney disease, with its commercial activity organized around its two marketed products:

• Vafseo (vadadustat): Oral HIF-PHI therapy for anemia due to CKD in dialysis patients.
• Auryxia (ferric citrate): Oral iron-based therapy addressing both phosphorus control (dialysis patients) and iron-deficiency anemia (non-dialysis CKD patients).
• Pipeline/Lifecycle Programs: Ongoing clinical and regulatory efforts to expand the utility of its approved therapies and evaluate additional indications within kidney disease.

---

3. Product Portfolio & Revenue Contributors

---

4. Competitive Landscape

                    High Dialysis-Channel Focus
                                 │
     Amgen (Epogen/Aranesp) ●    │           ● Akebia (Vafseo, Auryxia)
                                 │
   Fresenius Medical Care ●       │              ● GSK (daprodustat/Jesduvroq)
                                 │
─────────────────────────────────┼─────────────────────────────────
   Injectable Standard of Care    │              Oral / Novel Mechanism
                                 │
    AstraZeneca (Roxadustat, ex-US)●│           ● Keryx legacy Auryxia franchise
                                 │
                    Low Dialysis-Channel Focus

Competitors by Domain

Anemia Management in CKD/Dialysis

• Key Competitors: Amgen's long-standing ESA franchise (Epogen, Aranesp) remains the dominant standard of care; GSK's daprodustat (Jesduvroq) is a direct HIF-PHI competitor to Vafseo in the U.S. market.
• Dynamics: Akebia must displace decades-long ESA usage patterns and compete against GSK's rival oral HIF-PHI, with dialysis-organization formulary decisions and Medicare bundled-payment economics playing an outsized role in adoption.

Phosphate Binders / Iron Therapy

• Key Competitors: Other phosphate binders (e.g., sevelamer-based products) and iron-replacement therapies used in the CKD and dialysis population.
• Dynamics: Auryxia competes in an established, multi-player phosphate-binder and iron-therapy market where efficacy, tolerability, and payer coverage drive prescribing decisions.

---

5. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• FDA-approved, differentiated oral therapy: Vafseo's oral dosing is a genuine convenience and clinical-workflow differentiator versus injectable ESAs administered during dialysis sessions.
• Established commercial infrastructure: Existing sales relationships built around Auryxia provide a foundation for cross-promoting and building support for Vafseo within the same nephrology/dialysis customer base.
• Focused kidney-disease expertise: Deep specialization in CKD and dialysis-related conditions builds credibility with nephrologists and dialysis organizations.

Strategic Risks & Vulnerabilities

1. Concentrated customer base: U.S. dialysis care is dominated by two large organizations (DaVita and Fresenius Kidney Care), giving them significant negotiating leverage over formulary access and pricing.
   • Mitigation Strategy: Pursuing broad-based contracting and demonstrating clear clinical/cost value within the Medicare bundled-payment framework.
2. Direct competition from GSK's daprodustat: A well-capitalized competitor with its own HIF-PHI could slow Vafseo's uptake.
   • Mitigation Strategy: Differentiating on clinical data, safety profile, and commercial execution.
3. Reimbursement/bundled-payment risk: Changes to how CMS reimburses drugs within the ESRD bundle could affect the economics of adopting newer therapies like Vafseo.
   • Mitigation Strategy: Ongoing engagement with payers and policymakers to support appropriate reimbursement recognition for oral HIF-PHI therapy.

---

6. Financial Overview & Performance Matrix

---

7. Summary Conclusion

Akebia Therapeutics has built a focused kidney-disease franchise anchored by Auryxia's established phosphate-binder/iron-therapy business and the more recently launched Vafseo, an oral alternative to injectable ESA anemia therapy for dialysis patients. The combination gives Akebia both a current revenue base and a differentiated growth driver in a large, chronic patient population.

The company's long-term trajectory depends on how successfully it can convert Vafseo's oral-dosing advantage into meaningful share gains against entrenched injectable ESAs and GSK's competing oral HIF-PHI, all while navigating the concentrated dialysis-organization customer base and the complex Medicare bundled-payment reimbursement system that governs much of the U.S. dialysis drug market.